{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:41:31Z","timestamp":1789771291371,"version":"4.0.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Intravenous 5-fluorouracil (5-FU), in combination with oxaliplatin and folinic acid, makes up a chemotherapy regimen commonly referred to as FOLFOX. It is well-established for its efficacy in patients with advanced colorectal cancer; however, the benefits are accompanied by potential side effects that warrant careful consideration. Common toxicities can range from nausea and vomiting to neuropathy. Cardiotoxicities related to FOLFOX and fluoropyrimidines in general are extremely rare but can easily be fatal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 41-year-old woman who was recently diagnosed with stage IIIc colorectal cancer after she underwent a subtotal colectomy was admitted to the Oncology clinic for further treatment. Given her excellent performance status and lack of comorbidities, she was started on adjuvant FOLFOX therapy. Three days after her first dose, she presented to the emergency room with several episodes of self-limited substernal chest pain. An electrocardiogram was performed, which showed ST-segment elevation concerning for acute myocardial infarction. She was taken emergently for a coronary angiogram, which revealed no evidence of obstructive coronary artery disease or spontaneous coronary artery dissection. Her presentation was most consistent with coronary vasospasm secondary to her recently started chemotherapy regimen. She was monitored in the cardiac critical care unit; the next day, she developed a breakthrough chest pain and subsequently developed polymorphic ventricular tachycardia with loss of consciousness. It was found that she had suffered a breakthrough coronary vasospasm precipitating a life-threatening arrhythmia. She was started on calcium channel blockers and nitrates with the aim of preventing further episodes of her hypersensitivity-induced vasospasm, and she was eventually successfully rechallenged with a Nordic FLOX bolus-based regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In an unusual fashion, our patient developed ST-segment elevation myocardial infarction (STEMI) caused by coronary vasospasm, followed by delayed polymorphic ventricular tachycardia approximately 24\u2005h later. This dual-phase presentation and subsequent successful rechallenge with bolus-based 5-FU chemotherapy have not been previously reported.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1594338","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T05:30:48Z","timestamp":1757395848000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case Report: Coronary vasospasm precipitating STEMI and polymorphic ventricular tachycardia\u2014a case of cardiotoxicity from 5-FU based chemotherapy in a 41-year-old woman"],"prefix":"10.3389","volume":"12","author":[{"given":"Ammar","family":"Hasnie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Neace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Hesselson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Yafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Arbune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10316","DOI":"10.3748\/wjg.v20.i30.10316","article-title":"FOLFOX\/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy","volume":"20","author":"Mohelnikova-Duchonova","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3747\/co.v18i1.708","article-title":"Oxaliplatin: a review in the era of molecularly targeted therapy","volume":"18","author":"Alcindor","year":"2011","journal-title":"Curr Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"658636","DOI":"10.3389\/fonc.2021.658636","article-title":"5-Fluorouracil: a narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent","volume":"11","author":"Ghafouri-Fard","year":"2021","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.17219\/acem\/38154","article-title":"Evaluation of the toxicity of anticancer chemotherapy in patients with colon cancer","volume":"24","author":"Wiela-Hoje\u0144ska","year":"2015","journal-title":"Adv Clin Exp Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jemermed.2015.09.001","article-title":"A case of 5-fluorouracil-induced cardiac arrest","volume":"50","author":"Ray","year":"2016","journal-title":"J Emerg Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"B11","first-page":"3028","article-title":"In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/oxfordjournals.annonc.a010723","article-title":"The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture","volume":"7","author":"Cwikiel","year":"1996","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"De Forni","year":"1992","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.15420\/icr.2019.12","article-title":"Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions","volume":"14","author":"Chong","year":"2019","journal-title":"Interv Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1758835918780140","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0265767","DOI":"10.1371\/journal.pone.0265767","article-title":"The efficacy and safety of cardio-protective therapy in patients with 5-FU (fluorouracil)-associated coronary vasospasm","volume":"17","author":"Zafar","year":"2022","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"10197","DOI":"10.2147\/OTT.S264156","article-title":"Alternative treatment options in patients with colorectal cancer who encounter fluoropyrimidine-induced cardiotoxicity","volume":"13","author":"Saif","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clcc.2018.09.006","article-title":"Bolus 5-fluorouracil (5-FU) in combination with oxaliplatin is safe and well tolerated in patients who experienced coronary vasospasm with infusional 5-FU or capecitabine","volume":"18","author":"Chakrabarti","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaccao.2020.06.012","article-title":"How to diagnose and manage patients with fluoropyrimidine-induced chest pain: a single center approach","volume":"2","author":"Padegimas","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br J Cancer"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1594338\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T05:30:51Z","timestamp":1757395851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1594338\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":22,"alternative-id":["10.3389\/fcvm.2025.1594338"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1594338","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"article-number":"1594338"}}